Role of aliskiren in blood pressure control and renoprotection

International Journal of Nephrology and Renovascular Disease

Volumn 4, Issue , 2011, Pages 41-48

  Trimarchi, Hernán ^a  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Aliskiren; Chronic kidney disease; Hypertension; Proteinuria; Renoprotection

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; GLYCOPROTEIN P INHIBITOR; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN; RIFAMPICIN; VALSARTAN;

BINDING AFFINITY; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; MONOTHERAPY; NONHUMAN; POTASSIUM BLOOD LEVEL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UREA BLOOD LEVEL; URIC ACID BLOOD LEVEL;

EID: 79958830184     PISSN: None     EISSN: 11787058     Source Type: Journal    
DOI: 10.2147/IJNRD.S6653     Document Type: Review

References (95)

1. Kearny PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223.
2. Ritz E. Hypertension. The kidney is the culprit even in the absence of kidney disease. Kidney Int. 2007;71:371-372.
3. Levington S, Clarke R, Qizilbash N. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-1913.
4. United States Renal Data System 2010 Annual Data Report, CD Vol 1, Chapter 1, Table ei, page 48.
5. United States Renal Data System 2010 Annual Data Report, CD Vol 1, Chapter 2, Table 19i, page 61.
6. United States Renal Data System 2010 Annual Data Report, CD Vol 2, Chapter 2, Table 2 10ii, page 258.
7. Bakris GL. Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol. 2008;3 Suppl 1:S3-S10.
8. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Int Med. 1995;123:754-762.
9. De Zeew D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy:Lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
10. Chobanian AV, Bakris GL, Black HR. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
11. Bakris GL, Williams M, Dworkin L. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis. 2000;36:646-661.
12. De Zeew D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004;110:921-927.
13. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis. 2007;49 Suppl 2:S1-S179.
14. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
15. Mancia G, De Backer G, Dominiczak A. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105-1187.
16. Linas SL. Are two better than one? Angiotensin converting enzyme inhibitors plus angiotensin receptor blockers for reducing blood pressure and proteinuria in kidney disease. Clin J Am Soc Nephrol. 2008;3 Suppl:S17-S23.
17. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation. 2004;109:2492-2499.
18. Mooser V, Nussberger J, Jullierat L. Reactive hyperreninemia is a major determinant of plasma angiotensin II during ACE inhibition. J Cardiovasc Pharmacol. 1990;15:276-282.
19. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension. 1998;32:387-392.
20. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res. 1997;80: 219-227.
21. Fisher NDL, Allan D, Kifor I, et al. Responses of converting enzyme and renin inhibition: role of angiotensin II in humans. Hypertension. 1994;23:44-51.
22. Jeunemaitre X, Menard J, Nussberger J, et al. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38 560 A in hypertensive patients. Am J Hypertens. 1989;2:819-827.
23. Rahuel J, Rasetti V, Maibaum J, et al. Structure-based drug design: the discovery of novel non-peptide orally active inhibitors of human renin. Chem Biol. 2000;7:493-504.
24. Gradman AH, Schimieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
25. Trimarchi H, Orias M. Aliskiren and the kidney: beyond hypertension. Nephrology Reviews. 2009;1:e1-e4.
26. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun. 2003;308:698-705.
27. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
28. Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension. 2008;51:682-688.
29. Deinum J, Ronn B, Mathiesen E, et al. Increase in serum prorenin precedes onset of microalbuminuria in patients with insulin-dependent diabetes mellitus. Diabetologia. 1999;42:1006-1010.
30. Chiarelli F, Pomilio M, De Luca FA, et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr Nephrol. 2001;16:116-120.
31. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
32. Huang Y, Wongamorntham S, Kasting J, et al. Renin increases mesangial cell transforming growth factor beta and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int. 2006;69:105-113.
33. Benedict CR, Johnstone DE, Weiner DH. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction:a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:1410-1420.
34. Kehoe B, Keeton GR, Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron. 1986;44:51-57.
35. Brunner HR, Laragh JH, Baer L. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
36. Novartis. Tekturna (aliskiren) tablets 150 mg and 300 mg: US prescribing information. East Hanover (NJ): Novartis Pharmaceuticals Corporation. http://www.pharma.us.novartis.com/product/pi/pdf/tekturna.pdf. Accessed March 4, 2011.
37. Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47:515-531.
38. Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol. 2004;15:3126-3345.
39. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. 2008;48:1323-1338.
40. Vaidyanathan S, Jarugula V, Dieterich HA, et al. Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet. 2008;47:515-531.
41. European Medicines Agency. Rasilez: summary of product characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000780/WC500047010.pdf. Accessed March 4, 2011.
42. Zhao C, Vaidyanathan S, Yeh CM, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet. 2006;45:1125-1134.
43. Waldmeier F, Glaenzel U, Wirz B, et al. Absorption, distribution, metabolism, and elimination of the direct renin inhibitor aliskiren in healthy volunteers. Drug Metab Dispos. 2007;35:1418-1428.
44. Vaidyanathan S, Zhao C, Yeh C, et al. Pharmacokinetics and safety of the novel oral renin inhibitor aliskiren in patients with type 2 diabetes. Clin Pharmacol Ther. 2005;79 Suppl:S12.
45. Bartlett M, Vaidyanathan S, Karan RS, et al. Multiple dose pharmacokinetics of the direct renin inhibitor aliskiren in healthy Chinese subjects. Clin Pharmacol Ther. 2008;83 Suppl 1:S61-S62.
46. Vaidayanathan S, Jermany J, Yeh C, et al. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol. 2006;62:690-698.
47. Dieterich HA, Yeh C, Howard D, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract no. PIII-78]. Clin Pharmacol Ther. 2007;81 Suppl 1:S110.
48. Tapaninen T, Neuvonen PJ, NiemiM. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol. 2010;66:497-502.
49. Nguyen G, Delarue F, Burckle C, et al. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002;109:1417-1427.
50. Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension. 2008;51:15-18.
51. Luft FC, Winberger MH. Antihypertensive therapy with aliskiren. Kidney Int. 2008;73:679-683.
52. Oparil S, Yarows SA, Patel S. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized, double-blind trial. Lancet. 2007;370:221-229.
53. Nguyen G. The (pro)renin receptor: pathophysiological roles in cardiovascular and renal pathology. Curr Opin Nephrol Hypertens. 2007;16:129-133.
54. Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its affectiveness. Am J Hypertens. 2007;20:587-597.
55. Nussberger J, Aubert JF, Bouzourene K, et al. Renin inhibition by aliskiren prevents atherosclerosis progression. Comparison with irbesartan, atenolol, and amlodipine. Hypertension. 2008;51: 1306-1311.
56. Benedict CR, Johnstone DE, Weiner DH. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction:a report from the Registry of Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1994;23:1410-1420.
57. Kehoe B, Keeton GR, Hill C. Elevated plasma renin activity associated with renal dysfunction. Nephron. 1986;44:51-57.
58. Brunner HR, Laragh JH, Baer L. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
59. Fisher ND, Hollenberg MK. Renin inhibition: what are the therapeutic opportunities? J Am Soc Nephrol. 2005;16:592-599.
60. Richter WF, Whitby BR, Chou RC. Distribution of remikiren, a potent orally active inhibotor of human renin, in laboratory animals. Xenobiotica. 1996;26:243-254.
61. Feldman DL, Persohn E, Schitz H, et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens. 2006;8 Suppl A:A80.
62. Duggan ST, Chwieduk CM, Curran MP. Aliskiren. A review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs. 2010;70:2011-1049.
63. Oh BH, Mitchell J, Herron JR, et al. Aliskiren, an oral rennin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol. 2007;49:1157-1163.
64. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial [published erratum appears in Lancet. 2007;370(9598):1542]. Lancet. 2007;370:221-229.
65. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens. 2007;25: 217-226.
66. Kushiro T, Itakura H, Abo Y, et al. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res. 2006;29:997-1005.
67. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation. 2005;111:1012-1018.
68. Weir MR, Prescott MF, Bush C, et al. Antihypertensive efficacy of the direct renin inhibitor aliskiren in patients with diabetes, metabolic syndrome or obesity: a pooled analysis of 10 randomized trials [abstract no. P888]. Circulation. 2008;118:162.
69. Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens. 2008;26:589-599.
70. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. 2009;119:417-425.
71. Krone W, Hanefeld M, Meyer H-F, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens. 2011;25:186-195.
72. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens. 2007;20:11-20.
73. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension. 2003;42:1137-1143.
74. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9:163-175.
75. Black HR, Kribben A, Aguirre Palacios F, et al. Aliskiren as monotherapy or in combination with hydrochlorothiazide provides effective BP lowering in patients with systolic BP 160 # 180 mm Hg (ACQUIRE study) [abstract no. PO-15]. J Clin Hypertens. 2010; 12 Suppl 1:A24.
76. Chrysant SG, Murray AV, Hoppe UC, et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin. 2008;24:1039-1047.
77. Littlejohn TW 3rd, Trenkwalder P, Hollanders G, et al. Long-term safety, tolerability and efficacy of combination therapy with aliskiren and amlodipine in patients with hypertension. Curr Med Res Opin. 2009;25:951-959.
78. Geiger H, Barranco E, Gorostidi M, et al. Combination therapy with various combinations of aliskiren, valsartan, and hydrochlorothiazide in hypertensive patients not adequately responsive to hydrochlorothiazide alone. J Clin Hypertens. 2009;11:324-332.
79. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007;49:1047-1055.
80. Basile J, Babazadeh S, Lillestol M, et al. First-line aliskiren/hydrochlorothiazide combination treatment lowers BP more effectively than hydrochlorothiazide alone in older patients with stage 2 hypertension (ACTION study) [abstract no. PO-11]. J Clin Hypertens. 2010; 12 Suppl 1:A22.
81. Ferdinand K, Pool J, Weitzman R. Responses to aliskiren/HCTZ versus amlodipine on peripheral and central blood pressure in African American patients with stage 2 hypertension. J Am Coll Cardiol. 2010;55 (10 Suppl 1):A61.E586.
82. Zieve F, Yadao A, Yurkovic C, et al. Aliskiren with or without hydrochlorothiazide lowers blood pressure effectively in patients with stage 2 hypertension and metabolic syndrome [abstract no. PP.38.505]. J Hypertens. 2010;28 Suppl A:e600.
83. Townsend RR, Forker A, Rumpelt P, et al. Initial combination therapy with aliskiren/hydrochlorothiazide is more effective than amlodipine in patients with stage 2 systolic hypertension and diabetes mellitus [abstract no. LB-PO-03]. J Clin Hypertens. 2010;12:534.
84. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst. 2007;8:190-198.
85. Braun-Dullaeus RC, Zhang J, Hristoskova S, et al. First line therapy with aliskiren/amlodipine combination provides robust blood pressure reductions in patients with moderate to severe hypertension [abstract no. PO-22]. J Clin Hypertens. 2010;12 Suppl 1:A27.
86. Black H, Weinberger M, Purkayastha D, et al. Combination aliskiren/ amlodipine is more effective than amlodipine monotherapy in male and female African American subjects with stage 2 hypertension [abstract no. PO-20]. J Clin Hypertens. 2010;12 Suppl 1:A26.
87. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst. 2008;9:163-175.
88. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-2446.
89. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation. 2009;119:530-537.
90. McMurray JJV, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
91. Scirica BM, Morrow DA, Bode C, et al. Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial. Eur Heart J. 2010;31:1993-2005.
92. Cleland JGF, Coletta AP, Buga L, et al. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOPAF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail. 2010;12:623-629.
93. Novartis. Six months efficacy and safety of aliskiren therapy on top of standard therapy, on morbidity and mortality in patients with acute decompensated heart failure (ASTRONAUT) [ClinicalTrials.gov identifier NCT00894387]. US National Institutes of Health. http://www.clinicaltrials.gov. Accessed March 4, 2011.
94. Novartis. Aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE) [ClinicalTrials.gov identifier NCT00549757]. US National Institutes of Health. http://www.clinicaltrials.gov. Accessed March 4, 2011.
95. Novartis. Efficacy and safety of aliskiren and aliskiren/enalapril combination on morbi-mortality in patients with chronic heart failure (ATMOSPHERE) [ClinicalTrials.gov identifier NCT00853658]. US National Institutes of Health. http://www.clinicaltrials.gov. Accessed March 4, 2011.